ClinicalTrials.gg
CompletedNCT03398655OVALUpdated Jan 10, 2023

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

A Phase 3 interventional study of VB-111 + Paclitaxel and Placebo + Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics. Completed at 94 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 155 studies testing paclitaxel in Ovarian Neoplasms — 13 open to participants now, 21 under way, 6 of them phase 3. Paclitaxel · Ovarian Neoplasms.

Enrollment
12th of 143
408 · median 50
Started
2017
with 4 others
Phase 3
27 of 155
3 open now
Registered
121st of 155
by date

Among the 155 studies testing paclitaxel in Ovarian Neoplasms, this one is the 12th largest by enrollment of the 143 interventional ones that give a count, is one of 5 that started in 2017, is one of 27 in phase 3, and was the 121st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 155 studies testing paclitaxel in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing paclitaxel in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.

03

Conditions studied

  • Recurrent Platinum Resistant Ovarian Cancer

Keywords

  • Recurrent Ovarian cancer
  • Platinum resistant ovarian cancer
  • Ovarian cancer
  • Ovarian carcinoma
  • Epithelial ovarian cancer
  • paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients ≥18 years of age
  2. confirmed epithelial ovarian cancer and documented disease.
  3. Patients must have platinum-resistant disease
  4. Patients must have disease that is measurable according to 1.1 and require chemotherapy treatment.
  5. PS 0-1.
  6. Adequate hematological functions:

    • ≥ 1000/mm3
    • ≥ 100,000/mm3
    • PT and (seconds) \< 1.2 X . Patients who are anticoagulated do not need to meet criteria for PT and PTT.
  7. Patients who are known to carry a BRCA mutation may be enrolled only after (following PARP inhibitor treatment failure, or being intolerant of, or ineligible for PARP inhibitor treatment).

Exclusion criteria

Exclusion Criteria:

  1. Non-epithelial tumors (Carcino-sarcomas are excluded)
  2. Ovarian tumors with low malignant potential (i.e. borderline tumors) clear cell carcinomas, grade 1 serous tumors or mucinous tumors.
  3. History of other clinically active within 5 years of enrollment, except for tumors with a negligible risk for or death, such as adequately controlled basal-cell carcinoma, adequately controlled, non-metastatic squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.
  4. Previous ovarian cancer treatment with >5 anticancer regimens.
  5. Any prior radiotherapy to the pelvis or whole abdomen.
  6. Inadequate liver function, defined as serum creatinine > , unless calculated > 50ml/min (by Cockroft \& Gault formula):

    • Serum (total) > ULN (Exception: documented Gilbert's disease patients can be enrolled)
    • Alkaline phosphatase, /SGOT or ALT/SGPT ≥2.5 x ULN (or ≥ 5 x ULN in the presence of liver metastases).
  7. Inadequate renal function, defined as:

    • Serum creatinine > ULN OR
    • Calculated creatinine clearance \< 50ml/min (by Cockroft \& Gault formula)
  8. (NYHA) Grade II or greater congestive heart failure
  9. History of myocardial infarction or unstable angina within 6 months prior to day of randomization.
  10. History of stroke or within 6 months prior to day of randomization.
  11. Patient with proliferative and/or vascular retinopathy
  12. Known
  13. History of hemoptysis or active GI bleeding within 6 month prior to day of randomization
  14. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
  15. History of abdominal fistula or gastrointestinal perforation.
  16. Current signs and symptoms of bowel obstruction
  17. Uncontrolled active infection
  18. Patients who had evidence of disease progression during or up to 90 days from the last dose of the of platinum based therapy
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    Arm 1

    VB-111 + Paclitaxel

    Drug: VB-111 + Paclitaxel

  • Active comparator
    Arm 2

    Placebo + Paclitaxel

    Drug: Placebo + Paclitaxel

Interventions

  • DrugVB-111 + Paclitaxel

    Drug pages: Ofranergene obadenovec · Paclitaxel

    VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week

    Also known as: Ofranergene Obadenovec

  • DrugPlacebo + Paclitaxel

    Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: From randomization until death from any cause (up to 5 years after last study treatment)

  2. Progression Free Survival (PFS) by RECIST 1.1

    Time frame: From randomization until progression defined according to RECIST 1.1 or death, whichever occurs first (up to 5 years after last study treatment)

Secondary outcomes

  1. Combined CA-125 and RECIST 1.1 response (GCIG)

    Time frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment

  2. CA-125 Response (GCIG)

    Time frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment

  3. Objective response rate (ORR) by RECIST 1.1

    Time frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment

  4. OS100 for a sensitivity analysis of OS

    Time frame: From 100 days after date of study entry until the date of death from any cause, or up to 5 years after last study treatment

07

Study locations

94 sites
  • UAB Division of GYN Oncology
    Birmingham, Alabama 35344, United States
  • Western Regional Medical Center
    Goodyear, Arizona 85338, United States
  • Arizona Oncology Associates, PC - HAL - USO
    Phoenix, Arizona 85016, United States
  • Arizona Oncology Associates, PC - HAL - USO
    Tempe, Arizona 85284, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • UCLA-JCCC-Women's Health Clinical Research Unit
    Los Angeles, California 90095, United States
  • The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange
    Orange, California 92868, United States
  • University of California, Irvine Medical Center/Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • University of California - San Francisco
    San Francisco, California 94158, United States
  • Sansum Clinic - USO
    Santa Barbara, California 93105, United States
  • Olive View UCLA Medical Center
    Sylmar, California 91342, United States
  • Hartford HealthCare Cancer Institute at the Hospital of Central Ct
    Hartford, Connecticut 06053, United States
  • Hartford Healthcare
    Hartford, Connecticut 06106, United States
  • UF Health
    Gainesville, Florida 32610, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Midwestern Regional Medical Center, Inc
    Zion, Illinois 60099, United States
  • Parkview Cancer Institute
    Fort Wayne, Indiana 46845, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46131, United States
  • St. Vincent Gynecologic Oncology
    Indianapolis, Indiana 46260, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20902, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 20114, United States
  • University of Michigan
    Ann Arbor, Michigan 04801, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Henry Ford Health Hospital
    Detroit, Michigan 48202, United States
  • Dartmouth- Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Atlantic Health System/Morristown Medical Center
    Morristown, New Jersey 07928, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • New Mexico Cancer Care Alliance
    Albuquerque, New Mexico 87106, United States
  • Women's Cancer Care Associates, LLC
    Albany, New York 12208, United States
  • Westchester Medical Center
    Hawthorne, New York 10532, United States
  • Northwell Health Cancer Institute
    Lake Success, New York 11042, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    New York, New York 10016, United States
  • Health Quest Medical Practice, Division of Gynecology/Oncology Gyno Dyson Cancer Center Vassar Brothers Medical Center
    Poughkeepsie, New York 12601, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • UNC Chapel Hill
    Chapel Hill, North Carolina 27707, United States
  • Duke University-Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Sanford Medical Center
    Fargo, North Dakota 58122, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Womens Cancer Center/Kettering Cancer Care
    Kettering, Ohio 45429, United States
  • University of Oklahoma Health Sciences Center-Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Willamette Valley Cancer Institute and Research Center
    Eugene, Oregon 97401, United States
  • St. Luke's University Health Network
    Bethlehem, Pennsylvania 18015, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • The University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • West Penn Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • GHS Cancer Institute
    Greenville, South Carolina 29605, United States
  • Sanford Clinical Research
    Sioux Falls, South Dakota 57104, United States
  • Texas Oncology, Austin Central - USO
    Austin, Texas 78731, United States
  • Memorial Hermann
    Houston, Texas 77030, United States
  • UT Health
    San Antonio, Texas 78229, United States
  • Universtiy of Vermont
    Burlington, Vermont 05405, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Marshfield Clinic Cancer Care & Research Center
    Marshfield, Wisconsin 54449, United States
  • Froedtert and Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Rambam Medical Center
    Haifa, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Shaare Tzedek Medical Center
    Jerusalem, Israel
  • Rabin Medical Center
    Petach Tikva, 49100, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, Israel
  • Kaplan Medical Center, Department of Oncology
    Rehovot, Israel
  • Aichi Cancer Center
    Nagoya, Aichi, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • Ehime University Hospital
    Tōon, Ehime 791-0295, Japan
  • Kurume University Hospital
    Kurume, Fukuoka, Japan
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido, Japan
  • Iwate Medical University Hospital
    Shiwa-gun, Iwate 028-3695, Japan
  • Tohoku University Hospital
    Sendai, Myagi, Japan
  • National Defense Medical College Hospital
    Tokorozawa, Saitama 359-8513, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Koto, Tokyo 135-8550, Japan
  • Niigata Cancer Center Hospital
    Niigata, 951-8566, Japan
  • Hokkaido University Hospital
    Sapporo, 060-8648, Japan
  • Centrum Badan Klinicznych Jagiellonskiego Centrum Innowacji
    Kraków, 30-348, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie
    Olsztyn, 10-228, Poland
  • MedPolonia Sp. z o.o.
    Poznań, 60-375, Poland
  • Parc Taulí Hospital Universitari Edifici Santa Fe, Planta 0, Sala de recerca 3
    Barcelona, 08208, Spain
  • Institut Català d'Oncologia - Hospital Duran i Reynals
    Barcelona, 08908, Spain
  • Hospital Universitario de Donostia Edificio Onkologikoa- Planta baja, Sala de Ensayos Clinicos
    Donostia, 20014, Spain
  • Hospital Gregorio Marañon Módulo prefabricado Oncología, Planta Baja
    Madrid, 28009, Spain
  • MD Anderson Cancer Center Madrid Unidad de ensayos Clinicos
    Madrid, 28033, Spain
  • Hospital Universitario Clínico San Carlos.
    Madrid, 28040, Spain
  • Hospital Universitario Virgen del Rocío Servicio Oncología Médica. Ensayos Clínicos. Edificio CDCA
    Sevilla, 41013, Spain
  • Instituto Valenciano de Oncología Médica (IVO
    Valencia, 46009, Spain
  • Consorcio Hospitalario General Universitario de Valencia Servicio de Oncología Médica - Unidad de Investigación
    Valencia, 46014, Spain
08

References and documents

Publications

  • Arend RC, Monk BJ, Herzog TJ, Moore KN, Shapira-Frommer R, Ledermann JA, Tewari KS, Secord AA, Rachmilewitz Minei T, Freedman LS, Miller A, Shmueli SF, Lavi M, Penson RT. Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecol Oncol. 2021 May;161(2):496-501. doi: 10.1016/j.ygyno.2021.02.014. Epub 2021 Feb 23. PubMed 33637348 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jul 2022, 55 months.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 55 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2018
First posted
Jan 12, 2018
StartActual
Dec 19, 2017
Primary completionActual
Jul 19, 2022
CompletionActual
Jul 19, 2022
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03398655
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Collaborators
GOG Foundation
Responsible party
Sponsor
First posted
Jan 12, 2018
Start date
Dec 19, 2017
Primary completion
Jul 19, 2022
Completion
Jul 19, 2022
Last update
Jan 10, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ofranergene obadenovec · Paclitaxel

Start the discussion